Breast cancer is the world's most prevalent cancer. Although earlier detection and targeted treatment have resulted in high survival rates, many breast cancer survivors experience fear of cancer ...
MANCHESTER — HCA New England Healthcare, through HCA Healthcare Foundation’s Healthier Tomorrow Fund, has announced a $25,000 ...
(RTTNews) - RedHill Biopharma (RDHL) Tuesday announced that it has launched a Phase 2 trial to assess opaganib's ability to enhance darolutamide in treating metastatic castrate-resistant prostate ...
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced ...
Movember is proud to announce its latest prostate cancer investment of over $4.9 million. Eighteen grants (16 proposals and 2 ...
Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...
This World Cancer Day, Pfizer Canada ULC, together with Rethink Breast Cancer, Colorectal Cancer Canada, Lung Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback